• Artwork must be original and created by the submitter
• AI-generated or AI-assisted artwork will not be accepted
• Maximum of two submissions per artist
• Register your art submission by July 6
• Deliver artwork (clearly labeled with name and contact info) to the IBB front desk
  • July 15–17, between 8 a.m.-5 p.m. each day
  • Attendance at the July 23 Show is encouraged, but not required

⭐ Awards - All winning pieces to be displayed on the IBB website!

• Fan Favorite
  Voted on by IBB Art Gallery visitors from July 20–23. Celebrating the piece that resonates most with the community.
• 🔬 IBB ArtSci Award
  Recognizing a standout work that powerfully captures the intersection of art and science.
• 🧠 BRAINiArts Award
  Honoring creative expression inspired by neuroscience. 

Sponsored by Georgia Tech's Institute for Bioengineering and Bioscience (IBB), and the Bioengineering and Bioscience Unified Graduate Students (BBUGS)

Complimentary registration required for all attendees. Registration is now closed

Rapid-fire and poster presentation submission deadline April 29

Registration (without abstract submission) is open through May 14.

Conference Agenda

• 8:00 a.m. -   Registration/Breakfast
• 9:00 a.m. -   Opening Remarks
• 9:15 a.m. -   Abigail Wojtowicz, Medical Director, US Medical Strategy, Takeda
• 10:00 a.m. - Tina Dorr, Partner, Barnes & Thornburg Law
• 10:30 a.m. - Poster Session
• 11:45 a.m. - Cherry Wan, Senior Manager, Chemical Science, Alcon
• 12:15 p.m. - Lunch
• 1:15 p.m. -   Bruno Marques, Senior Vice President, Technical Operations, Morphocell Technologies
• 2:00 p.m. -   Jianming Li, Senior Program Officer, Venture Well
• 3:00 p.m -    Break
• 3:15 p.m -    Rapid Fire Presentations (three minutes each)
• 4:00 p.m. -   Career Panel Discussion
• 5:00 p.m. -   Closing Remarks
• 5:10 p.m. -   Reception and Award Ceremony
• 7:00 p.m. -   Adjourn

Rapid Fire Presenters

1. Maya Zhang - PI, Andrés García, "Developing an Intestine Organ Chip with Controlled Oxygen Gradients"
2. Aileen He - PI, Ahmet Coskun,"DYNAMICS: A Trajectory-based Framework for Inferring Non-contact, Cytokine-mediated Cell-cell Communication from Spatial Transcriptomics"
3. Spencer Hayes - PI, Felipe Quiroz, "Engineering Tunable Phase-Separating IDP Polymers for Synthetic Organelle Assembly in Human Cells
4. Aref Valipour - PI, Nick Housley, "Multiscale Microvascular Models"
5. Luiza DaMotta - PI, Andrés García, "Hydrogel-based Co-delivery of Antimicrobial Agents Eliminates Established Infection and Promotes Bone Healing"
6. Nisha Raman - PI, Mark Prausnitz, "Advancing Microneedle Technology for High Dose Delivery of Protein Therapeutics"
7. Vanessa Dartora - PI, Alyssa Panitch, "Population-Informed Biomaterial Design: Engineering EPC Secretomes for Precision Wound Healing"
8. Athena Chien - PI, Craig Forest, "Membrane-resolved Epithelial electrophysiology revealed using extracellular electrochemical impedance spectroscopy (EEIS)"

Element Bio Workshop Registration | ibidi Workshop Registration

Agenda

• 8:00 a.m. Registration/Breakfast
• 8:30 a.m. Element Bio Workshop
• 10:00 a.m. Break/Networking
• 10:30 a.m. ibidi Workshop Part 1
• 11:15 a.m. ibidi Workshop Part 2
• 12:00 p.m. IBB Core Facilities Lab Tours
• 1:30 p.m. Adjourn (transit to GT-GLC)

Vendor Workshop Details 

• Element’s AVITI24™/VITARI™: A Multiomic NGS Platform for Deeper Insights and Higher Throughput
  In this session, Element will provide a technical overview of the AVITI platform family. AVITI delivers dependable, cost-effective NGS for foundational applications including gene expression profiling, single-cell sequencing, and targeted sequencing, with straightforward operation suited for shared cores and research labs. AVITI24 enables higher-resolution multiomic assays and Direct In Sample Sequencing, integrating spatial RNA, protein, and morphology readouts in a single run. Attendees will be introduced to VITARI, the world’s first high-throughput bench-top sequencer, designed for scalable performance and maximum flexibility.
• ibidi Part 1 - Free Partnership Offerings for Core Facilities and ibidi Overview
  This session includes a general review of ibidi products for live cell imaging, immunofluorescence, and 3D cell culture. Additionally, it will cover ibidi partnerships with Core Facilities.
• ibidi Part 2 - NEW Micro Illumination System – Benchtop Microfluidics and Microstructuring
  An informational session and live demo of the benchtop UV illumination device. The session will cover applications like 3D microstructuring, light-induced wound healing, micropatterning, hydrogel-structuring, and more. 

For details on the SEASR (Southeastern Association of Shared Resources) Conference at the Georgia Tech Learning Center on June 3-4, 2026, visit their conference page at https://seasr.abrf.org/.

Meetings are open to Members, Guests, Sponsors, Partners, and presenting Entrepreneurs from any of our Keiretsu Forum Global chapters and regions.

Due to SEC 506(c) regulations guests MUST pre-register to attend our meetings.

• Informative lectures from leading experts
• Hands-on training in small groups
• Proteomics and metabolomics applications
• Native mass spectrometry and UHMR
• HDX-MS and cross-linking MS
• Data analysis using multiple software platforms (e.g., MaxQuant, Compound Discoverer, Proteome Discoverer, etc.)

AGENDA OUTLINE
Oct. 7: 9 a.m. - 5 p.m.
Oct. 8: 9 a.m. - 5 p.m.
Oct. 9: 9 a.m. - 4:30 p.m.

We’re taking a break from the labs and the summer heat to celebrate community. 

Open to all in the bio-community, while supplies last.

Register HERE to participate virtually

Ashish Ranjan is an Endowed Professor in the Department of Radiation Oncology. He also serves as Vice Chair for Comparative Oncology and Research Innovation and Director of the Veterinary Research and Oncology Clinic. He earned his B.V.Sc. degree (DVM equivalent) from Madras Veterinary College, in Chennai, India, followed by a Ph.D. in biomedical and veterinary sciences from Virginia Tech. Ranjan was then a visiting fellow at the Center for Interventional Oncology, Department of Radiology and Imaging Sciences at the National Institutes of Health (NIH).

Ranjan's research interests are in the application of device-directed nanoparticles for solid tumor chemo-immunotherapy. His lab is actively engaged in preclinical and bench-to-bedside veterinary clinical trials and has received funding from several federal, state, and private sources. Ranjan has received several distinguished awards, including the NIH Merit Award. He also serves on the Scientific Advisory Board of Focused Ultrasound Foundation, UK's Humanimal Trust, and NIH panels.

Faculty host: Yue Chen

 

Direct inquiries to connect@ibb.gatech.edu

Meetings are open to Members, Guests, Sponsors, Partners, and presenting Entrepreneurs from any of our Keiretsu Forum Global chapters and regions.

Due to SEC 506(c) regulations guests MUST pre-register to attend our meetings.

Meetings are open to Members, Guests, Sponsors, Partners, and presenting Entrepreneurs from any of our Keiretsu Forum Global chapters and regions.

Due to SEC 506(c) regulations guests MUST pre-register to attend our meetings.

Meetings are open to Members, Guests, Sponsors, Partners, and presenting Entrepreneurs from any of our Keiretsu Forum Global chapters and regions.

Due to SEC 506(c) regulations guests MUST pre-register to attend our meetings.

Meetings are open to Members, Guests, Sponsors, Partners, and presenting Entrepreneurs from any of our Keiretsu Forum Global chapters and regions.

Due to SEC 506(c) regulations guests MUST pre-register to attend our meetings.

Meetings are open to Members, Guests, Sponsors, Partners, and presenting Entrepreneurs from any of our Keiretsu Forum Global chapters and regions.

Due to SEC 506(c) regulations guests MUST pre-register to attend our meetings.

Meetings are open to Members, Guests, Sponsors, Partners, and presenting Entrepreneurs from any of our Keiretsu Forum Global chapters and regions.

Due to SEC 506(c) regulations guests MUST pre-register to attend our meetings.

Meetings are open to Members, Guests, Sponsors, Partners, and presenting Entrepreneurs from any of our Keiretsu Forum Global chapters and regions.

Due to SEC 506(c) regulations guests MUST pre-register to attend our meetings.

BIO
Marcela Maus grew up in New York, NY and attended Massachusetts Institute of Technology for her undergraduate degree in Biology and Literature. She then earned her MD, PhD from the University of Pennsylvania School of Medicine where she studied the biology of human T cell activation under the direction of her PhD mentor, Dr. Carl June. After completing her doctorate degrees, Marcela did a one-year postdoctoral fellowship with Dr. Kathy High at the Children’s Hospital of Philadelphia studying patient immune responses to liver-directed AAV-mediate gene transfer as a treatment for hemophilia. She then completed her clinical training in internal medicine, hematology, and oncology as a resident at the University of Pennsylvania Health System and a fellow at Memorial Sloan Kettering Cancer Center. While at Memorial Sloan Kettering, she worked in Michel Sadelain’s lab to engineer new genetically modified T cells to target the cancer-testis antigen NY-ESO-1 and received specialized training in Phase I developmental therapeutics. She was also awarded a K08 grant by the NIH to facilitate her transition to a faculty position.

Following her extensive training (11 years), Marcela returned to the University of Pennsylvania in 2012, where she was recruited by her former PhD mentor, to expand their research efforts in the development of CAR T cells for lymphoma, myeloma, and other cancers. While there, Marcela continued her efforts on preclinical development of CAR T cells and correlative studies of CAR T cell-related toxicities and resistance to therapies. They discovered and reported on the first cases of anaphylaxis to CAR T cells and off target cross-reactivity. She also led an entire arc of translational research, from preclinical testing to a first-in-human clinical trial of EGFRvIII CAR T cells for treatment of recurrent glioblastoma. Correlative data collected from this trial led to an understanding of CAR T resistant mechanisms that have led further refinement of these CAR T cells, which is one current area of focus in her current laboratory and has led to the development of another Phase I clinical trial for GBM patients.

Now, Dr. Maus is a Professor of Hematology and Oncology at Massachusetts General Hospital and Harvard Medical School, where she runs a laboratory focused on developing and improving CAR T cell therapy for cancer patients while also periodically attending for the bone marrow transplant service. Marcela is the Paula O-Keeffe Endowed Chair of the Massachusetts General Hospital Cancer Center and the Director of the Cellular Immunotherapy Program. She has won numerous awards for her transformative research and is achieving her goal of using science to determine the best way to treat patients by harnessing the power of the immune system to solve intractable problems like cancer. She also enjoys training clinicians and scientists and watching her mentees succeed and become independent scientists and collaborators.

He is Professor of Bioengineering and Materials Science at UC Berkeley and Faculty Scientist at Lawrence Berkeley National Laboratory. He is a Fellow of the Royal Society of Chemistry, the American Institute for Medical and Biological Engineering, the Materials Research Society and the American Association for the Advancement of Science. In addition to his research, he mentors and teaches students in the fields of biomaterials design, materials science, polymer science, and nanomedicine.

Faculty host: Felipe Quiroz

 

Special emphasis is given to Tissue Engineering and Regenerative Medicine and particular applications and more details are described on the lab web page.

Faculty host: Alexander Vlahos

 

BIO
Jeffrey Hubbell is a pioneer in the field of immuno-modulatory materials whose research spans biology, chemistry, and engineering to generate novel solutions to common health problems. His work focuses on using biomaterials and engineered proteins to enhance the body’s own immune system to fight inflammatory and autoimmune disorders, allergies, and disease states like cancers. With more than 400 papers and 100 issued US patents, Hubbell uses biomaterials and protein engineering approaches to investigate topics in regenerative medicine and immunotherapeutics. In regenerative medicine, he develops both materials and protein therapeutics to address issues such as chronic wound healing in diabetes and bone repair after trauma. In immunotherapeutics, he pursues nanomaterials in vaccination for infectious disease and cancer as well as targeted therapy with RNA, protein-material conjugates for inverse vaccines to induce antigen-specific tolerance in autoimmunity and allergy, and in protein therapy to tip immune balances toward aggression in immuno-oncology and toward tolerance in inflammatory disease. His interests are both basic and translational, having founded or co-founded six biomedical companies based on his technology.

Before moving to New York University, Hubbell was at the University of Chicago in the Pritzker School of Molecular Engineering, where he helped build its strength in immunoengineering. Prior to that, he was on the faculty of the Swiss Federal Institute of Technology Lausanne (EPFL, where he served as founding Director of the Institute of Bioengineering and Dean of the School of Life Sciences), the Swiss Federal Institute of Technology Zurich (ETHZ) and University of Zurich, the California Institute of Technology, and the University of Texas in Austin. He was elected to the US National Academy of Engineering in 2010, the National Academy of Medicine in 2019, the American Academy of Arts and Sciences in 2021, and the National Academy of Sciences in 2023.

• Do you have a patentable invention and want to protect it?
• Interested in commercializing your research either through licensing to an existing company or a startup?
• Want to learn about the commercialization resources available for entrepreneurs?

Stop by the IP and Commercialization Office Hours in the IBB atrium and meet with experts from the Office of Technology Licensing and Quadrant-i. We are at your service!  

The Experts:

• Cynthia Sundell, Senior Director of Life Sciences and Quadrant-i Principal
• Harold Solomon, Quadrant-i Principal
• Kashmira Kulkarni, Licensing Associate Office of Technology Licensing